Alnylam

glossary | media kit | careers | contact us

Capella

Search
Welcome to Capella

Capella is the brightest star in the constellation Auriga. It is also a unified, focused vocal arrangement. For Alnylam, Capella is our online voice for communicating the scientific progress we are making as we translate the science of RNAi into human clinical experience and ultimately towards the development of innovative medicines for patients.

Send us your feedback
Subscribe
See Alnylam At

09/08/2011-09/10/2011
7th Annual Meeting of Oligonucleotide Therapeutics Society

11/20/2011-11/22/2011
International Symposium on FAP
Tags
Regulus, Leadership in RNAi, Delivery, Clinical Trials, RNA-platform, TTR-Mediated Amyloidosis, Severe Hypercholesterolemia, Podcasts, 5x15, RNAi Clinical Trials, Respiratory Syncytial Virus, Liver Cancers, Hemophilia, Huntington’s Disease, RNAi Therapeutics, Refractory Anemia, hemoglobinopathy, Biotherapeutics, VaxiRNA, Huntington's Disease
Archives
Twitter

loading tweets...

More Tweets

Monthly Archives For: February 2012

February 9, 2012

Novel Method for Monitoring RNAi Activity in Blood Samples

Our scientists discovered a new method for monitoring RNAi activity in blood samples. The results were presented at the Keystone Gene Silencing by small RNAs symposium (Vancouver, February 7-12). This new method, circulating extracellular RNA detection (cERD), allows quantitative measurement of tissue-specific mRNA silencing from biological fluids including blood and cerebrospinal fluid (CSF).